Selected article for: "complement activation and CoV infection"

Author: Barkoff, Courtney M.; Mousa, Shaker A.
Title: Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
  • Cord-id: f6t0fkez
  • Document date: 2020_12_24
  • ID: f6t0fkez
    Snippet: Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the pot
    Document: Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the potential impact of complement activation in COVID-19 and possible treatments targeting the complement system.

    Search related documents:
    Co phrase search for related documents
    • access program and low mortality: 1, 2
    • access program and lung function: 1
    • access program and lung injury: 1, 2
    • access program and lymphocyte count: 1
    • activation site and acute lung injury: 1
    • activation site and lung injury: 1, 2